MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fphar.2026.1723656

Медицинская библиотека · Frontiers in pharmacology · 2026

Effects of sleeve gastrectomy on rivaroxaban pharmacokinetics, efficacy, and safety.

Alqahtani Saeed, Almutairi Anfal, Aldajani Faten, Basudan Manar, Alzahrani Arwa, Alenazi Maha, Alsarhani Emad, Alsubaie Abdulaziz, Almaghrabi Alhassan, Bamehriz Fahad, Alsubaie Hamad, Algahtani Farjah

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Thromboembolic events are potentially serious complications in patients undergoing bariatric surgery. Several studies have investigated the use of rivaroxaban in patients undergoing bariatric surgery. Further evidence is required to determine whether postsurgical anatomical and physiological changes affect the pharmacokinetics of rivaroxaban. This study aimed to investigate the pharmacokinetic, efficacy, and safety of rivaroxaban in patients who underwent sleeve gastrectomy surgery.

METHODS

Included patients who admitted for sleeve gastrectomy surgery and were scheduled to receive prophylactic doses of rivaroxaban. Pre- and post-operative rivaroxaban plasma concentrations were determined. Efficacy and safety were assessed 6 and 9 months after surgery.

Results

Twenty patients (40% males) were included in the study. The average body weight was 117.6 ± 21.2 kg. The average AUC values before, after, and 7-day after bariatric surgery were 5.83 (1.23), 5.34 (1.87), and 6.29 (2.12) μg·h mL-1, respectively. The average Cmax before, after, and 7-day after bariatric surgery were 0.45 (0.2), 0.37 (0.17), and 0.48 (0.23) μg mL-1, respectively. No significant differences were observed in the rivaroxaban PK parameters. No thrombosis events were reported over 6 or 9 months. In addition, 100% of the participants experienced no significant bleeding events or other adverse effects associated with rivaroxaban during the trial period.

CONCLUSION

Rivaroxaban 10 mg shows promise as a potential medication for VTE prophylaxis after bariatric surgery. However, future studies with larger, more diverse populations are needed to confirm these findings and strengthen their applicability in clinical practice and to determine the optimal dosage and long-term safety profile in this patient population.

Для цитирования: Alqahtani Saeed, Almutairi Anfal, Aldajani Faten, Basudan Manar, Alzahrani Arwa, Alenazi Maha, Alsarhani Emad, Alsubaie Abdulaziz, Almaghrabi Alhassan, Bamehriz Fahad, Alsubaie Hamad, Algahtani Farjah. Effects of sleeve gastrectomy on rivaroxaban pharmacokinetics, efficacy, and safety.. Frontiers in pharmacology. 2026. DOI: 10.3389/fphar.2026.1723656.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.